Cancer and Stem Cell Biology

癌症和干细胞生物学研究中心（CSCB） 摘要 癌症和干细胞生物学研究计划（CSCB）由MBBS的Gay Crooks主任领导， 专门从事造血干/祖细胞移植，联合主任Brigitte Gomperts，医学博士， 研究肺癌的发生和微环境的作用。CSCB链接基础和翻译 研究干细胞和恶性肿瘤之间共有的生物学过程的研究人员。计划会员 期望详细了解正常和异常细胞自我更新的机制， 分化将揭示新的生物学见解癌症的开始，进展和复发，从而 从而能够探索新的治疗靶点和生物标志物。CSCB基础、翻译和临床 研究人员研究了正常干细胞和它们的恶性对应物，它们来自两种生物来源， 造血和上皮细胞。两个组织平台之间的科学互动通过共享而整合 共同的概念框架和实验工具。该计划的目标是了解内在的 以及控制健康组织内稳态的外在机制，这些机制在恶性肿瘤中出错， 这些癌症治疗的机制。三个具体目标指导实现方案目标。目标1-目标 了解上皮干细胞的生物学如何在恶性转化和正常过程中受到调节 发展目的2-明确造血干细胞生长和分化的调控机制 以及在恶性转化、正常发育和移植后的祖细胞。目标3-目的 确定微环境在肿瘤形成和干细胞调节中的作用。 CSCB课程有来自16个部门的36名教师，横跨加州大学洛杉矶分校的四所学校和附属机构 加州理工学院，共同提供所需的专业知识的广度和深度，以实现科学和方案 目标.在此之前，项目成员的工作效率很高，与633篇癌症出版物合作 项目期间，31%是跨计划的，6%是计划内的，44%是 高影响力（IF ≥10，或领域领先）期刊。成员们得到了11，389，786美元的癌症基金的支持， 其中270万美元（23%）来自NCI，810万美元（71%）来自同行评审。程序科学高度依赖于 联合气候变化委员会（JCCC），其重要成员使用了所有六种共享资源、种子和影响赠款计划、空间 关键调查人员的分配、征聘和留用。每个CSCB调查员都有主导利益 在造血干细胞或上皮干细胞中，尽管所有组织中干细胞和癌症的共同生物学特性 类型已经导致了一个非常肥沃的和交互式的跨平台程序环境。这些相互作用 受益于JCCC和UCLA广泛干细胞研究中心（BSCRC）之间的密切合作 在过去的12年里。几乎每一个CSCB的研究者都致力于三个具体目标中的至少两个，使用 动物模型系统、人类多能干细胞和原代人类组织的组合， 基本的生物过程，并揭示癌症治疗的新机会。

CANCER AND STEM CELL BIOLOGY RESEARCH PROGRAM (CSCB) ABSTRACT The Cancer and Stem Cell Biology Research Program (CSCB) is led by Director Gay Crooks, MBBS, who specializes in hematopoietic stem/progenitor cell transplantation and Co-Director Brigitte Gomperts, MD, who studies lung carcinogenesis and the role of the microenvironment. CSCB links basic and translational investigators studying biological processes shared between stem cells and malignancy. Program members expect that a detailed understanding of the mechanisms of normal and aberrant cell self-renewal and differentiation will reveal novel biological insights into cancer initiation, progression, and recurrence, thereby enabling exploration of novel therapeutic targets and biomarkers. CSCB basic, translational, and clinical researchers study normal stem cells and their malignant counterparts originating from two biological sources, hematopoiesis and epithelia. Scientific interactions between the two tissue platforms integrate by sharing common conceptual frameworks and experimental tools. The Program objective is to understand the intrinsic and extrinsic mechanisms that control homeostasis in healthy tissues that go awry in malignancy, and to harness these mechanisms for cancer treatment. Three specific aims guide achieving the Program objective. Aim 1- To understand how the biology of epithelial stem cells is regulated during malignant transformation and normal development. Aim 2- To define the mechanisms that regulate growth and differentiation of hematopoietic stem and progenitor cells during malignant transformation, normal development, and after transplantation. Aim 3- To determine the role of the microenvironment in tumor formation and stem cell regulation. The CSCB program has 36 faculty from 16 departments spanning four UCLA schools and affiliated institution Caltech, that together provide the breadth and depth of expertise needed to achieve scientific and programmatic goals. Program members are highly productive and collaborative with 633 cancer publications during the prior project period, 31% of which are inter-programmatic, 6% of which are intra-programmatic, and 44% of which are in high-impact (IF ≥10, or field leading) journals. Members have support from $11,389,786 in cancer funding, of which $2.7M (23%) is from the NCI and $8.1M (71%) is peer-reviewed. Program science is highly dependent on the JCCC, with significant member use of all six Shared Resources, the Seed and Impact grant programs, space allocations, and recruitment and retention of key investigators. Each CSCB investigator has a dominant interest in either hematopoietic or epithelial stem cells, although the shared biology of stem cells and cancer in all tissue types has led to an immensely fertile and interactive Program environment across platforms. These interactions benefit from a close collaboration between the JCCC and the UCLA Broad Stem Cell Research Center (BSCRC) over the past 12 years. Almost every investigator in CSCB works on at least two of the three specific aims, using combinations of animal model systems, human pluripotent stem cells, and primary human tissues to uncover basic biologic processes and reveal new opportunities for cancer treatment.